Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker

Morio, Hanae; Sun, Yuchen; Harada, Manami; Ide, Hideyuki; Shimozato, Osamu; Zhou, Xujia; Higashi, Kenjirou; Yuki, Ryuzaburo; Yamaguchi, Naoto; Hofbauer, Josefina Piñón; Guttmann‐Gruber, Christina; Anzai, Naohiko; Akita, Hidetaka; Chiba, Kazuhiro; Furihata, Tomomi

doi:10.1248/bpb.b17-00743

Cited by 12 publications

(10 citation statements)

References 19 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, Ct-OATP1B3 mRNA is present in extracellular vesicles derived from CRC patients and can be detected in serum samples. The detection of Ct-OATP1B3 mRNA in CRC-derived extracellular vesicles as a diagnostic biomarker is worthy of further study ( 36 ).…”

Section: Candidate Rna Molecules As Biomarkers For Crcmentioning

confidence: 99%

Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer – From the Body Fluid to Tissue Level

Han

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

In recent years, the diagnosis and treatment of colorectal cancer (CRC) have been continuously improved, but the mortality rate continues to be high, especially in advanced patients. CRC patients usually have no obvious symptoms in the early stage and are already in the advanced stage when they are diagnosed. The 5-year survival rate is only 10%. The blood markers currently used to screen for CRC, such as carcinoembryonic antigen and carbohydrate antigen 19-9, have low sensitivity and specificity, whereas other methods are invasive or too expensive. As a result, recent research has shifted to the development of minimally invasive or noninvasive biomarkers in the form of body fluid biopsies. Non-coding RNA molecules are composed of microRNAs, long non-coding RNAs, small nucleolar RNAs, and circular RNAs, which have important roles in the occurrence and development of diseases and can be utilized for the early diagnosis and prognosis of tumors. In this review, we focus on the latest findings of mRNA-ncRNA as biomarkers for the diagnosis and prognosis of CRC, from fluid to tissue level.

show abstract

Section: Candidate Rna Molecules As Biomarkers For Crcmentioning

confidence: 99%

Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer – From the Body Fluid to Tissue Level

Han

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…KRTAP5-4 and MAGEA3 mRNA in the serum of patients could be used as diagnostic biomarkers to detect CRC 79. Ct-OATP1B3 mRNA was present in EVs derived from HCT116, HT-29, and SW480 cells that were declared to be serum-based CRC biomarkers,80 Huang et al, introduced UBC, H3F3A, HIST2H2AA3, AKT3, and HSPA1B as hub genes in bioinformatic analysis to serve as diagnostic markers and therapeutic targets of CRC in the future 81Table 3 shows all of these results.…”

Section: Resultsmentioning

confidence: 99%

“…27,917,441UBC, H3F3A, HIST2H2AA3, AKT3, HSPA1BGSE100206, GSE100063, GSE32323 (Bioinformatic Analysis)–29 patients, 49 control/tissue and Blood–Huang, 2018 81doi: 10.21037/tcr.2018.05.32OATP1B3Exosome Isolation kit (Thermo Fisher Scientific), PVDF filter and Differential centrifugationTEM, Western blottingqRT-PCR, Western blotting–HCT116, HT-29, and SW480 cell line, Blood of Mouse–Morio, 2018 8029,491,222 Abbreviations: TEM, transmission electron microscopy; NTA, nanoparticle tracking analyzer; PEG, polyethylene glycol polymer; ELISA, enzyme-linked immunosorbent assay; SEM, scanning electron microscope; DLS, dynamic light-scattering.…”

Section: Resultsmentioning

confidence: 99%

<p>Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review</p>

Vafaei¹,

Fattahi²,

Ebrahimi³

et al. 2019

CMAR

View full text Add to dashboard Cite

Nearly half of patients with colorectal cancer (CRC), the third leading cause of cancer deaths worldwide, are diagnosed in the late stages of the disease. Appropriate treatment is not applied in a timely manner and nearly 90% of the patients who experience metastasis ultimately die. Timely detection of CRC can increase the five-year survival rate of patients. Existing histopathological and molecular classifications are insufficient for prediction of metastasis, which limits approaches to treatment. Detection of reliable cancer-related biomarkers can improve early diagnosis, prognosis, and treatment response prediction and recurrence risk. Circulating tumor cells (CTCs) and exosomes in peripheral blood can be used in a liquid biopsy to assess the status of a tumor. Exosomes are abundant and available in all fluids of the body, have a high half-life and are released by most cells. Tumor-derived exosomes are released from primary tumors or CTCs with selective cargo that represents the overall tumor. The current systematic review highlights new trends and approaches in the detection of CRC biomarkers to determine tumor signatures using CTC and exosomes. When these are combined, they could be used to guide molecular pathology and can revolutionize detection tools. Relevant observational studies published until July 24, 2019 which evaluated the expression of tumor markers in CTCs and exosomes were searched in PubMed, Scopus, Embase, and ISI Web of Science databases. The extracted biomarkers were analyzed using String and EnrichR tools.

show abstract

“…The gene encoding SLCO1B3 is a member of the SLCO gene superfamily, which encodes organic anion transporting polypeptide (OATP). OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting the reuptake of conjugated bilirubin reuptake into the liver [42]; however, high levels of OATP1B3 transcripts are significantly associated with colorectal cancer and prostate cancer, suggesting that OATP1B3 represents a promising biomarker for those cancers [43,44]. Therefore, we suggest that by upregulating the expression of these genes, EB1 promotes cell proliferation, tumor growth, and metastasis of HCC.…”

Section: Plos Onementioning

confidence: 89%

Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis

et al. 2020

View full text Add to dashboard Cite

This study was performed to determine the clinical significance of adenomatous polyposis coli (APC)-binding protein end-binding 1 (EB1) in hepatocellular carcinoma (HCC) and to characterize its biochemical role in comparison with previous reports. We performed immunohistochemical staining to detect EB1 expression in tissues from 235 patients with HCC and investigated its correlations with clinicopathological features and prognosis. We also investigated the roles of EB1 in cell proliferation, migration, and tumorigenesis in vitro and in vivo by siRNA-and CRISPR/Cas9-mediated modulation of EB1 expression in human HCC cell lines. The results showed that EB1 expression was significantly correlated with several important factors associated with tumor malignancy, including histological differentiation, portal vein invasion status, and intrahepatic metastasis. Patients with high EB1 expression in HCC tissue had poorer overall survival and higher recurrence rates than patients with low EB1 expression. EB1 knockdown and knockout in HCC cells reduced cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo. Further, genes encoding Dlk1, HAMP, and SLCO1B3 that were differentially expressed in association with EB1 were identified using RNA microarray analysis. In conclusion, elevated expression of EB1 promotes tumor growth and metastasis of HCC. EB1 may serve as a new biomarker for HCC, and genes coexpressed with EB1 may represent potential targets for therapy.

show abstract

Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker

Cited by 12 publications

References 19 publications

Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer – From the Body Fluid to Tissue Level

Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer – From the Body Fluid to Tissue Level

<p>Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review</p>

Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis

Contact Info

Product

Resources

About